Pathology News

Leica Biosystems Launches a 4-Plex Fluorescent Detection Kit to Advance Cancer Research

Leica Biosystems Launches a 4 Plex Fluorescent Detection Kit to Advance Cancer Research

Leica Biosystems, a Danaher company and a global leader in anatomic pathology solutions, streamlines multiplex immunofluorescence (IF) forĀ  oncology and translational research with the launch of its BOND 4-Plex Fluorescent Detection Kit for research use only (RUO). The new pre-assembled kit empowers researchers to achieve consistent, high-quality results while preserving tissue morphology.

Multiplex-IF enables spatial characterization of the tumor microenvironment, such as assessing coexpression of immune checkpoints (e.g., PD- 1/PD-L1) and T-cell markers (e.g., CD3, CD8) within the same tissue section. By allowing the simultaneous detection of multiple biomarkers withĀ  high sensitivity and clear spectral separation, multiplex IF provides in depth insights into tumor biology and immune response.

Traditional workflows often require tedious and extensive reagent preparation, manual steps, and harsh staining conditions that can compromiseĀ  tissue quality and reproducibility. The Leica Biosystems BOND 4-Plex Fluorescent Detection Kit RUO reduces these barriers with a pre-assembledĀ  kit that integrates seamlessly with the Leica Biosystems BOND RX automated stainer.

ā€œOur mission is to empower cancer researchers with innovative tools that provide deeper insights and advance the frontiers of cancer research,ā€ said Karan Arora, Senior Vice President, Advanced Assays, AI, and Pharma Partnerships at Leica Biosystems. ā€œWith the 4-plex fluorescent detection kit,Ā  we’re removing workflow barriers and enabling scientists to generate reliable, reproducible data, while preserving the integrity of precious tissueĀ  samples. This launch highlights our ongoing investment in technologies that drive discovery and translational breakthroughs, providing researchersĀ  with advanced tools to expand understanding of the tumor microenvironment.ā€

4 Plex Fluorescent Detection Kit

Featuring a pre-assembled design, the kit simplifies reagent setup and reduces preparation time, enabling direct loading onto the BOND RX stainer. Standardized protocols minimize variability and human error, supporting consistent results across experiments with reproducible performance. The innovation also helps in preserving both tissue morphology and antigenicity for accurate downstream analysis. This is achieved through the use of aĀ  gentle elution buffer that operates at low temperatures, ensuring the tissue’s structural integrity remains intact.

The BOND 4-Plex Fluorescent Detection Kit RUO is now available to research laboratories across the United States, with additional regionsĀ  anticipated throughout 2026. For more information or to request a demonstration, click here.

For Research Use Only. Not For Use In Diagnostic Procedures.

About Leica Biosystems

Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the onlyĀ  company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step.Ā  The company’s mission of ā€œAdvancing Cancer Diagnostics, Improving Livesā€ is at the heart of its corporate culture. Leica Biosystems is proud to be aĀ  Danaher Corporation subsidiary.

About Danaher

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher’s advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the timeĀ  and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow.

Share this article

Follow us

Get Pathology News Delivered to Your Inbox

Learn More

Leica Biosystems logo

Leica Biosystems News

Leica Biosystems Solutions
Go to Top